Abstract:The use of antagonists for each adenosine receptor (AR) subtype as potent clinical candidates is of growing interest due to their involvement in the treatment of various diseases. The recent resolution of several A(1) and A(2A) ARs X-ray structures provides opportunities for structure-based drug design. In this study, we describe the discovery of novel A(1)AR antagonists by applying a multistage virtual screening approach, which is based on random forest (RF), e-pharmacophore modeling and docking methods. A multistage virtual screening approach was applied to screen the ChemDiv library (1,492,362 compounds). Among the final hits, 22 compounds were selected for further radioligand binding assay analysis against human A(1)AR, and 18 compounds (81.82% success) exhibited nanomolar or low micromolar binding potency (K-i). Then, we selected six compounds (pK(i) > 6) to further evaluate their antagonist profile in a cAMP functional assay, and we found that they had low micromolar antagonistic activity (pIC(50) = 5.51-6.38) for the A(1)AR. Particularly, four of six compounds (pK(i) > 6) showed very good affinity (pKi = 6.11-7.13) and selectively (>100-fold) for A(1)AR over A(2A)AR. Moreover, the novelty analysis suggested that four of six compounds (pK(i) > 6) were dissimilar to existing A(1)AR antagonists and hence represented novel A(1)AR antagonists. Further molecular docking and molecular dynamics (MD) studies showed that the three selective compounds 15, 20 and 22 were stabilized (RMSlig value <= 2 angstrom) inside the binding pocket of AAR with similar orientations to the docking pose in 100-ns MD simulations, whereas they escaped from the binding area of A(2A)AR with larger values of RMSlig (RMSlig >= 2 angstrom). We hope that these findings provide new insights into the discovery of drugs targeting A(1)AR and facilitate research on new drugs and treatments for A(1)AR-related human pathologies. (C) 2019 Elsevier Masson SAS. All rights reserved.

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Synthesis of N-pyrimidinyl-2-phenoxyacetamides As Adenosine A2A Receptor Antagonists

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines As A(2a) Adenosine Receptor Antagonists for the Treatment of Parkinson'S Disease

Identification of Novel, Water-Soluble, 2-Amino-n-pyrimidin-4-yl Acetamides As A2A Receptor Antagonists with in Vivo Efficacy

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

2,6-Diaryl-4-phenacylaminopyrimidines As Potent and Selective Adenosine A(2A) Antagonists with Reduced Herg Liability.

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Design and Synthesis of Five‐membered Heterocyclic Derivatives of Istradefylline with Comparable Pharmacological Activity

Synthesis of Alkyne Derivatives of a Novel Triazolopyrazine As A2A Adenosine Receptor Antagonists.

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides As A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy.

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

Discovery of a 4-Aryloxy-1h-pyrrolo[3,2-c]pyridine and a 1-Aryloxyisoquinoline Series of TRPA1 Antagonists

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Replacement of Amide with Bioisosteres Led to a New Series of Potent Adenosine A2A Receptor Antagonists.

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Identification of Anti‐parkinson's Disease Lead Compounds from Aspergillus Ochraceus Targeting Adenosin Receptors A2A

2,6-Diaryl-4-acylaminopyrimidines As Potent and Selective Adenosine A2A Antagonists with Improved Solubility and Metabolic Stability